[go: up one dir, main page]

PE20142460A1 - Composiciones farmaceuticas orales estables de liberacion inmediata que contienen prasugrel - Google Patents

Composiciones farmaceuticas orales estables de liberacion inmediata que contienen prasugrel

Info

Publication number
PE20142460A1
PE20142460A1 PE2014001488A PE2014001488A PE20142460A1 PE 20142460 A1 PE20142460 A1 PE 20142460A1 PE 2014001488 A PE2014001488 A PE 2014001488A PE 2014001488 A PE2014001488 A PE 2014001488A PE 20142460 A1 PE20142460 A1 PE 20142460A1
Authority
PE
Peru
Prior art keywords
pharmaceutical compositions
compositions containing
immediate release
release oral
stable pharmaceutical
Prior art date
Application number
PE2014001488A
Other languages
English (en)
Inventor
Andras Feher
Zsolt Zsigmond
Peter Tonka-Nagy
Gyorgy Ujfalussy
Original Assignee
Egyt Gyogyszervegyeszeti Gyar
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Egyt Gyogyszervegyeszeti Gyar filed Critical Egyt Gyogyszervegyeszeti Gyar
Publication of PE20142460A1 publication Critical patent/PE20142460A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

REFERIDA A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE UNA BASE DE PRASUGREL MICRONIZADA, ALMIDON O UN DERIVADO DEL ALMIDON TAL COMO ALMIDON PREGELATINIZADO Y ESTEARILFUMARATO DE SODIO O ACIDO ESTEARICO. DICHA COMPOSICION ES UTIL EN EL TRATAMIENTO DE EVENTOS ATEROTROMBOTICOS EN PACIENTES QUE PADECEN SINDROME CORONARIO AGUDO
PE2014001488A 2012-04-02 2013-04-02 Composiciones farmaceuticas orales estables de liberacion inmediata que contienen prasugrel PE20142460A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US13/437,087 US8603537B2 (en) 2012-04-02 2012-04-02 Prasugrel containing quickly released stable oral pharmaceutical compositions

Publications (1)

Publication Number Publication Date
PE20142460A1 true PE20142460A1 (es) 2015-02-05

Family

ID=48626468

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2014001488A PE20142460A1 (es) 2012-04-02 2013-04-02 Composiciones farmaceuticas orales estables de liberacion inmediata que contienen prasugrel

Country Status (17)

Country Link
US (1) US8603537B2 (es)
EP (1) EP2833871B1 (es)
KR (1) KR20150003726A (es)
CN (1) CN103717209B (es)
AU (1) AU2013245425A1 (es)
CA (1) CA2869281A1 (es)
CO (1) CO7111279A2 (es)
EA (1) EA028329B1 (es)
HU (1) HUE034564T2 (es)
IL (1) IL234931A0 (es)
MX (1) MX2014011033A (es)
NZ (1) NZ631426A (es)
PE (1) PE20142460A1 (es)
PH (1) PH12014502221A1 (es)
PL (1) PL2833871T3 (es)
UA (1) UA116204C2 (es)
WO (1) WO2013150322A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2360159A1 (de) 2010-02-11 2011-08-24 Ratiopharm GmbH Prasugrel in mikronisierter, kristalliner Form und pharmazeutische Zusammensetzung davon
WO2014060560A1 (en) * 2012-10-19 2014-04-24 Sanovel Ilac Sanayi Ve Ticaret A.S. Solid oral formulations of prasugrel
CN103610674B (zh) * 2013-12-09 2015-01-07 海南灵康制药有限公司 一种含微粉化的普拉格雷的固体制剂
WO2016122421A1 (en) 2015-01-29 2016-08-04 Pharmactive Ilaç Sanayi Ve Ticaret A.Ş. Stable pharmaceutical compositions containing prasugrel base
EP3158993A1 (en) * 2015-10-22 2017-04-26 Zaklady Farmaceutyczne Polpharma SA Process for preparing a tablet comprising prasugrel or pharmaceutically acceptable salt thereof
GR1009230B (el) 2016-10-12 2018-02-22 Φαρματεν Αβεε Φαρμακευτικο σκευασμα που περιλαμβανει βεσυλικη πρασουγρελη

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI101150B (fi) 1991-09-09 1998-04-30 Sankyo Co Menetelmä lääkeaineina käyttökelpoisten tetrahydrotienopyridiinin johd annaisten valmistamiseksi
EP1298132B1 (en) 2000-07-06 2006-11-22 Sankyo Company, Limited Hydropyridine derivative acid addition salts
UA79498C2 (en) 2002-09-05 2007-06-25 Kissei Pharmaceutical Intermediates for preparation of phenoxy-acetic derivates and processes of their preparation
US20050195079A1 (en) 2004-03-08 2005-09-08 David Cohen Emergency situation detector
TWI318571B (en) 2005-06-10 2009-12-21 Lilly Co Eli Formulation of a thienopyridine platelet aggregation inhibitor
CA2672134C (en) 2006-12-07 2015-02-10 Daiichi Sankyo Company, Limited Solid medicinal preparation containing mannitol or lactose
CN101594865A (zh) 2006-12-07 2009-12-02 第一三共株式会社 含有低取代的羟基丙基纤维素的药物组合物
US20090291138A1 (en) 2006-12-07 2009-11-26 Daiichi Sankyo Company, Limited Film-coated preparation having improved stability
CN101568339A (zh) 2006-12-07 2009-10-28 伊莱利利公司 普拉格雷的制品
US20110201814A1 (en) 2006-12-07 2011-08-18 Daiichi Sankyo Company Limited Method for producing solid preparation
KR101647842B1 (ko) 2006-12-07 2016-08-11 다이이찌 산쿄 가부시키가이샤 저장 안정성이 개선된 의약 조성물
CN101177430A (zh) 2007-12-11 2008-05-14 鲁南制药集团股份有限公司 氢化吡啶衍生物及其盐的制备方法
DE112009000268T5 (de) 2008-02-06 2011-06-01 Helm Ag Prasugrel-Salze mit verbesserten Eigenschaften
WO2009129983A1 (en) 2008-04-21 2009-10-29 Ratiopharm Gmbh Acid addition salts of prasugrel and pharmaceutical compositions comprising the same
EP2112155B1 (en) 2008-04-25 2010-09-29 Sandoz AG Hydrogensulfate salt of 2-acetoxy-5-(a-cyclopropylcarbonyl-2-fluorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine and its preparation
US20090281136A1 (en) * 2008-05-08 2009-11-12 Sandeep Mhetre Prasugrel pharmaceutical formulations
WO2010070677A2 (en) 2008-12-15 2010-06-24 Glenmark Generics Limited A process for the preparation of prasugrel and its pharmaceutically acceptable salts thereof
WO2010094471A1 (en) 2009-02-17 2010-08-26 Krka, D. D., Novo Mesto Pharmaceutical compositions comprising prasugrel base or its pharmaceutically acceptable acid addition salts and processes for their preparation
US8772488B2 (en) 2009-03-31 2014-07-08 Shanghai Institute Of Pharmaceutical Industry Crystals of prasugrel hydrobromate
GB2469883A (en) 2009-04-30 2010-11-03 Sandoz Ag Novel crystalline form of Prasugrel hydrogensulphate
EP2451816A4 (en) 2009-07-06 2013-02-27 Glenmark Generics Ltd CRYSTALLINE FORM OF PRASUGREL HYDROBROMIDE AND PROCESS FOR PREPARING THE SAME
KR20110024057A (ko) 2009-09-01 2011-03-09 한미홀딩스 주식회사 신규한 프라수그렐 황산수소염의 결정다형
WO2011036533A1 (en) * 2009-09-23 2011-03-31 Glenmark Pharmaceuticals Limited Pharmaceutical composition comprising prasugrel and triflusal
DE102009052887B4 (de) 2009-11-13 2016-09-15 Otto Bock Healthcare Products Gmbh Verfahren zur Steuerung eines orthetischen oder prothetischen Gelenkes einer unteren Extremität
CZ2009762A3 (cs) 2009-11-16 2011-05-25 Zentiva, K. S. Nové soli 5-[2-cyklopropyl-1-(2-fluorfenyl)-2-oxoethyl]-4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl acetátu známého pod nechráneným názvem prasugrel a zpusob jejich výroby
EP2360159A1 (de) 2010-02-11 2011-08-24 Ratiopharm GmbH Prasugrel in mikronisierter, kristalliner Form und pharmazeutische Zusammensetzung davon
CA2788764A1 (en) 2010-03-23 2011-09-29 Alembic Pharmaceuticals Limited A process for the preparation of prasugrel hcl salt
CN101804042A (zh) * 2010-04-16 2010-08-18 山东新华制药股份有限公司 普拉格雷片剂的制备方法

Also Published As

Publication number Publication date
NZ631426A (en) 2015-09-25
AU2013245425A1 (en) 2014-10-23
UA116204C2 (uk) 2018-02-26
HK1198466A1 (en) 2015-05-08
US8603537B2 (en) 2013-12-10
CA2869281A1 (en) 2013-10-10
PH12014502221A1 (en) 2015-01-12
IL234931A0 (en) 2014-12-31
HUE034564T2 (en) 2018-02-28
EA028329B1 (ru) 2017-11-30
CO7111279A2 (es) 2014-11-10
EP2833871B1 (en) 2017-07-19
EP2833871A1 (en) 2015-02-11
EA201491831A1 (ru) 2015-01-30
CN103717209B (zh) 2017-07-18
PL2833871T3 (pl) 2017-12-29
WO2013150322A1 (en) 2013-10-10
MX2014011033A (es) 2015-09-23
KR20150003726A (ko) 2015-01-09
US20130259904A1 (en) 2013-10-03
CN103717209A (zh) 2014-04-09

Similar Documents

Publication Publication Date Title
CY1123476T1 (el) Τροποποιητες πυρηνικης μεταφορας και χρησεις αυτων
EA201690102A1 (ru) Фармацевтическая композиция, содержащая диметилфумарат, для введения в низкой суточной дозе
MX2014015217A (es) Una composicion farmaceutica que contiene acido nicotinico y/o nicotinamida y/o triptofano para influir positivamente en la microbiota intenstinal.
CY1116698T1 (el) Συνθεση περιεχοντας υπερ-μικρονοποιημενο παλμιτοϋλ-αιθανολαμιδιο
CR20160006A (es) Derivados de pirrolamida sustituidos con glioxamida y su uso como medicamentos para el tratamiento de la hepatitis b
UY33183A (es) Compuestos inhibidores de virus flaviviridae, composición farmaceutica que los contiene y su uso en la manufactura de un medicamento
MX2013002453A (es) Analogos deuterados de pridopidina utiles como estabilizadores dopaminergicos.
MX375001B (es) Formulacion de premezcla de dexmedetomidina.
MX2016014547A (es) Compuestos para tratar atrofia muscular espinal.
CO6620065A2 (es) Compuestos heteroarilo nitrogenados
UY35040A (es) Pirrolopirimidinilamino-benzotiazolonas sustituidas
DOP2011000382A (es) Sulfonamidas heterociclicas, usos y composiciones farmaceuticas de las mismas
PE20142460A1 (es) Composiciones farmaceuticas orales estables de liberacion inmediata que contienen prasugrel
MX348064B (es) Imidazopiridazinas sustituidas con amino.
MD4556C1 (ro) Compuşi inhibitori ai activităţii catehol O-metiltransferazei
MX2020005735A (es) Derivados de glutarimida, uso de los mismos, composición farmacéutica basada en los mismos y métodos para producir derivados de glutarimida.
BR112012013487A2 (pt) Composições de amantadina e métodos de uso
PH12015501096A1 (en) Composition for immediate and extended release
NZ720328A (en) Pyranochromenyl phenol derivative, and pharmaceutical composition for treating metabolic syndrome or inflammatory disease
AR093126A1 (es) Formulaciones de liberacion modificada para oprozomib
ECSP13012838A (es) Nuevos compuestos de benzodioxol-piperazina
CO6491033A2 (es) 5-3,4-dicloro-fenil- n-(2-hidroxi-cicloheexil)- 6-(2,2,2-trifluoro etoxi)- nicotinamida y sales de la misma, como agentes que elevan el colesterol hdl
MX363389B (es) Composicion farmaceutica que comprende ivabradina amorfa.
AR083095A1 (es) Cocristal de aprepitant l-prolina y composicion farmaceutica
UY35004A (es) Forma amorfa estabilizada de la agomelatina, su procedimiento de preparación y las composiciones farmacéuticas que la contienen

Legal Events

Date Code Title Description
FD Application declared void or lapsed